OVID THERAPEUTICS INC.

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

18 окт 2023 08:00:01 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

10 окт 2023 08:00:01 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

26 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

20 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

30 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

04 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

01 авг 2023 08:00:01 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

28 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Added to Russell 3000® Index

26 июн 2023 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

05 май 2023 07:30:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

01 май 2023 06:00:00 Источник Nasdaq GlobeNewswire

Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting

27 апр 2023 14:30:14 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

10 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

13 мар 2023 08:00:01 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum

09 мар 2023 08:00:01 Источник Nasdaq GlobeNewswire

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

08 мар 2023 08:00:00 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

28 фев 2023 08:00:02 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

08 фев 2023 08:00:01 Источник Nasdaq GlobeNewswire

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

05 янв 2023 08:00:45 Источник Nasdaq GlobeNewswire

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

02 дек 2022 10:00:00 Источник Nasdaq GlobeNewswire